Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jin-Sying Lin

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Blood|October 12, 2010
Determination of acute lung injury after repeated platelet transfusionsLaurence Corash, Jin Sying Lin, Claire D Sherman, et al.
Transfusion Medicine (Oxford, England)|September 20, 2022
Pathogen inactivation treatment of triple-dose apheresis platelets with amotosalen and ultraviolet a lightLaura Infanti, Vildana Pehlic, Sandra Mitrovic, et al.
Transfusion|December 24, 2005
Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trialEdward Snyder, Jeffrey McCullough, Sherrill J Slichter, et al.
Transfusion|March 15, 2006
Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot studyAnne C Simonsen, Pär I Johansson, Maureen G Conlan, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|November 20, 2019
Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpuraOlivier Garraud, Sandrine Malot, Raoul Herbrecht, et al.
Transfusion|April 25, 2009
Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component useJean Claude Osselaer, Chantal Doyen, Laurence Defoin, et al.
Transfusion|January 10, 2006
Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A lightScott Murphy, Edward Snyder, Ritchard Cable, et al.
Transfusion|April 3, 2018
Amotosalen/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host diseaseGrace Castro, Patricia A Merkel, Hannah E Giclas, et al.
Transfusion|October 2, 2019
Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 daysLaura Infanti, Andreas Holbro, Jakob Passweg, et al.
British Journal of Haematology|June 1, 2019
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemiaYesim Aydinok, Antonio Piga, Raffaella Origa, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Blood|October 12, 2010
Determination of acute lung injury after repeated platelet transfusionsLaurence Corash, Jin Sying Lin, Claire D Sherman, et al.
Transfusion Medicine (Oxford, England)|September 20, 2022
Pathogen inactivation treatment of triple-dose apheresis platelets with amotosalen and ultraviolet a lightLaura Infanti, Vildana Pehlic, Sandra Mitrovic, et al.
Transfusion|December 24, 2005
Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trialEdward Snyder, Jeffrey McCullough, Sherrill J Slichter, et al.
Transfusion|March 15, 2006
Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot studyAnne C Simonsen, Pär I Johansson, Maureen G Conlan, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|November 20, 2019
Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpuraOlivier Garraud, Sandrine Malot, Raoul Herbrecht, et al.
Transfusion|April 25, 2009
Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component useJean Claude Osselaer, Chantal Doyen, Laurence Defoin, et al.
Transfusion|January 10, 2006
Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A lightScott Murphy, Edward Snyder, Ritchard Cable, et al.
Transfusion|April 3, 2018
Amotosalen/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host diseaseGrace Castro, Patricia A Merkel, Hannah E Giclas, et al.
Transfusion|October 2, 2019
Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 daysLaura Infanti, Andreas Holbro, Jakob Passweg, et al.
British Journal of Haematology|June 1, 2019
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemiaYesim Aydinok, Antonio Piga, Raffaella Origa, et al.
Pageof 2